RxDoctor Payments Data

Kyle Riganati, DO

Family Medicine · Lykens, PANPI 1407111404

Payments from drug & device makers

$8,738in general payments, 2019–2025

Across 550 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$978
  • GSK$928
  • Lilly USA, LLC$819
  • AstraZeneca$604
  • Pfizer$520
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,60598%
  • Education$1342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,738 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$505,202
Medicare patients
748
Services billed
9,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$200,522
OzempicSemaglutide137$181,091
TrulicityDulaglutide151$167,211
JardianceEmpagliflozin136$140,259
XareltoRivaroxaban134$100,332
MounjaroTirzepatide70$88,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$58,385
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog56$48,033
EntrestoSacubitril/Valsartan44$40,099
RybelsusSemaglutide32$38,634
Tresiba Flextouch U-200Insulin Degludec38$38,213
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$30,266
MyrbetriqMirabegron41$25,347
FarxigaDapagliflozin Propanediol21$24,480
RexultiBrexpiprazole16$22,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$819$255,791221 claims
Novo NordiskOzempic, Rybelsus$1,118$219,726169 claims
PfizerEliquis$520$200,522249 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$316$167,797167 claims
Johnson & JohnsonXarelto$315$100,332134 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$928$81,020115 claims
AstraZenecaBreztri Aerosphere, Farxiga$604$54,74769 claims
NovartisEntresto$174$40,09944 claims
Astellas Pharma US IncMyrbetriq$267$25,34741 claims
Otsuka America Pharmaceutical, Inc.Rexulti$119$22,67416 claims
AbbVieLinzess$978$15,60128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lykens

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →